Adult Glioblastoma Clinical Trial
Official title:
Phase II Trial of Dasatinib in Patients With Recurrent Glioblastoma Multiforme
Verified date | July 2019 |
Source | National Cancer Institute (NCI) |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This phase II trial studies how well dasatinib works in treating patients with glioblastoma multiforme or gliosarcoma that has come back. Dasatinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
Status | Completed |
Enrollment | 64 |
Est. completion date | September 4, 2018 |
Est. primary completion date | March 9, 2011 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Histologically proven diagnosis of GBM; gliosarcoma is also an eligible diagnosis - The patient must consent to submission of tissue for central pathology review - Patients who have already undergone central pathology review through their enrollment on another Radiation Therapy Oncology Group (RTOG) GBM trial do not need to consent to having their material re-reviewed by the central pathologist for this study - All patients must consent to molecular analysis of pre-dasatinib tumor tissue - Patients accrued to stage I (closed to accrual) or stage IB (opened to accrual May 5, 2009) must have tumors overexpressing at least 2 known dasatinib targets (i.e., SRC proto-oncogene, non-receptor tyrosine kinase [SRC], v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog [KIT], platelet-derived growth factor receptor [PDGFR], or ephrin type-A receptor 2 [EPHA2]) - Patients accrued to stage II (cohort closed; not currently applicable) do not require overexpression of SRC, KIT, PDGFR, or EPHA2 - History and physical examination, including height and weight, within 10 days prior to registration on study - Brain magnetic resonance imaging (MRI) with and without gadolinium within 10 days prior to registration on study - Contrast-enhanced computed tomography (CT) scans are allowed for patients who cannot undergo MRI scanning - Karnofsky performance status >= 60 - Absolute neutrophil count (ANC) >= 1,000 cells/mm^3 - Platelets >= 75,000 cells/mm^3 - Hemoglobin (Hgb) >= 8.0 g/dl; (note: the use of transfusion or other intervention to achieve Hgb >= 8.0 g/dl is acceptable) - Leukocytes >= 3,000 cells/mm^3 - Absolute lymphocyte count (ALC) >= 500 cells/mm^3 - Total bilirubin =< 1.5 X institutional upper limit of normal (ULN) - Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 2.5 institutional upper limit of normal - Creatinine =< 3 X institutional upper limit of normal or creatinine clearance >= 60 mL/min/1.73 m^2 for patients with creatinine levels above institutional normal - All patients must have undergone prior treatment with radiotherapy and temozolomide; no other prior treatments are allowed - There must be unequivocal radiographic evidence for tumor progression by MRI or CT scan, and the same type of scan (i.e., MRI or CT) must be used throughout the period of protocol treatment for tumor measurement; patients must be on a stable or decreasing dose of corticosteroids for at least 5 days before the baseline MRI/CT is performed - Patients having undergone recent surgery for recurrent/progressive disease are eligible as long as they have recovered from the effects of surgery; patients who recently underwent resection without measurable disease post-operatively are also eligible - Measurable disease is not required for eligibility in patients who recently underwent resection as long as the following conditions are met as applicable: - Progression of disease led to the surgery - Gliadel wafers were not placed during the most recent surgery - Neither convection enhanced delivery nor catheters for infusion of chemotherapy were used during the most recent surgery - Radioactive seeds were not placed during the most recent surgery - The histology of the most recent surgery documented recurrent/persistent/progressive malignant glioma - Women of childbearing potential must have a negative beta human chorionic gonadotropin (B HCG) pregnancy test =< 3 days prior to registration - Patient must sign study-specific informed consent prior to study entry Exclusion Criteria: - Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 3 years; (for example, carcinoma in situ of the breast, oral cavity, or cervix are all permissible) - Radiotherapy within 4 weeks or temozolomide within 14 days prior to registration or failure to recover from adverse events of either radiotherapy or temozolomide - Patients may not be receiving any other investigational agents - Severe, active comorbidity, defined as follows: - Any clinically significant cardiovascular disease including the following: - Unstable angina and/or congestive heart failure requiring hospitalization within the past 6 months - Transmural myocardial infarction or ventricular tachyarrhythmia within the past 6 months - Prolonged corrected QT interval (QTc) > 480 msec (Fridericia correction) - Ejection fraction less than institutional normal - Major conduction abnormality (unless a cardiac pacemaker is present) - Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration - Chronic obstructive pulmonary disease exacerbation or other respiratory illness requiring hospitalization or precluding study therapy at the time of registration - Acquired immune deficiency syndrome (AIDS) based upon current Centers for Disease Control and Prevention (CDC) definition; note, however, that human immunodeficiency virus (HIV) testing is not required for entry into this protocol - Pregnancy or women of childbearing potential and men who are sexually active and not willing/able to use medically acceptable forms of contraception; breastfeeding should be discontinued if the mother is treated with dasatinib - History of allergic reactions attributed to compounds of similar chemical or biologic composition to dasatinib - Patients who require concurrent treatment with any medications or substances that are potent inhibitors or inducers of cytochrome P450, family 3, subfamily A, polypeptide 4 (CYP3A4) are ineligible - Patients must not be taking hepatic enzyme inducing antiepileptic drugs (EIAEDs); if patients were previously on EIAEDs that have been discontinued, patients must have been off EIAEDs for >= 2 weeks prior to initiation of dasatinib - Patients who require antacids should use short-acting, locally active agents (e.g., Maalox, Mylanta etc.); however, these agents should not be taken within either 2 hours before or 2 hours after the dasatinib dose - Use of antithrombotic and/or antiplatelet agents (e.g., warfarin, heparin, low molecular weight heparin, aspirin, clopidogrel, ticlopidine, Aggrenox) - Use of ibuprofen or non-steroidal anti-inflammatory drugs (NSAIDs) - Patients with any condition (e.g., gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for intravenous [IV] alimentation, prior surgical procedures affecting absorption, or active peptic ulcer disease) that impairs their ability to swallow and retain dasatinib tablets are excluded - Prior treatment with stereotactic radiosurgery (including Gamma-Knife, Cyberknife, or other variants) or brachytherapy |
Country | Name | City | State |
---|---|---|---|
Canada | London Regional Cancer Program | London | Ontario |
Canada | CHU de Quebec-L'Hotel-Dieu de Quebec (HDQ) | Quebec City | Quebec |
Canada | Allan Blair Cancer Centre | Regina | Saskatchewan |
Saudi Arabia | King Faisal Specialist Hospital and Research Centre | Riyadh | |
United States | Abington Memorial Hospital | Abington | Pennsylvania |
United States | Cleveland Clinic Akron General | Akron | Ohio |
United States | Summa Akron City Hospital/Cooper Cancer Center | Akron | Ohio |
United States | American Fork Hospital / Huntsman Intermountain Cancer Center | American Fork | Utah |
United States | AnMed Health Hospital | Anderson | South Carolina |
United States | Saint Vincent Anderson Regional Hospital/Cancer Center | Anderson | Indiana |
United States | Michigan Cancer Research Consortium NCORP | Ann Arbor | Michigan |
United States | Saint Joseph Mercy Hospital | Ann Arbor | Michigan |
United States | Sutter Cancer Centers Radiation Oncology Services-Auburn | Auburn | California |
United States | Summa Barberton Hospital | Barberton | Ohio |
United States | Franciscan Saint Francis Health-Beech Grove | Beech Grove | Indiana |
United States | Boca Raton Regional Hospital | Boca Raton | Florida |
United States | Boston Medical Center | Boston | Massachusetts |
United States | University of Vermont College of Medicine | Burlington | Vermont |
United States | University of Vermont Medical Center | Burlington | Vermont |
United States | Fairview Ridges Hospital | Burnsville | Minnesota |
United States | Cooper Hospital University Medical Center | Camden | New Jersey |
United States | Sutter Cancer Centers Radiation Oncology Services-Cameron Park | Cameron Park | California |
United States | Aultman Health Foundation | Canton | Ohio |
United States | Cape Radiation Oncology | Cape Girardeau | Missouri |
United States | Mercy San Juan Medical Center | Carmichael | California |
United States | Sandra L Maxwell Cancer Center | Cedar City | Utah |
United States | Medical University of South Carolina | Charleston | South Carolina |
United States | Novant Health Presbyterian Medical Center | Charlotte | North Carolina |
United States | University of Cincinnati/Barrett Cancer Center | Cincinnati | Ohio |
United States | John B Amos Cancer Center | Columbus | Georgia |
United States | Mercy Hospital | Coon Rapids | Minnesota |
United States | Good Samaritan Hospital - Dayton | Dayton | Ohio |
United States | Grandview Hospital | Dayton | Ohio |
United States | Miami Valley Hospital | Dayton | Ohio |
United States | Samaritan North Health Center | Dayton | Ohio |
United States | Veteran Affairs Medical Center | Dayton | Ohio |
United States | Beaumont Hospital-Dearborn | Dearborn | Michigan |
United States | Ascension Saint John Hospital | Detroit | Michigan |
United States | Delaware County Memorial Hospital | Drexel Hill | Pennsylvania |
United States | City of Hope Comprehensive Cancer Center | Duarte | California |
United States | Northeast Radiation Oncology Center | Dunmore | Pennsylvania |
United States | Fairview-Southdale Hospital | Edina | Minnesota |
United States | Union Hospital of Cecil County | Elkton | Maryland |
United States | Green Bay Oncology - Escanaba | Escanaba | Michigan |
United States | Blanchard Valley Hospital | Findlay | Ohio |
United States | Genesys Regional Medical Center-West Flint Campus | Flint | Michigan |
United States | Hurley Medical Center | Flint | Michigan |
United States | Holy Cross Hospital | Fort Lauderdale | Florida |
United States | Atrium Medical Center-Middletown Regional Hospital | Franklin | Ohio |
United States | Unity Hospital | Fridley | Minnesota |
United States | University of Florida Health Science Center - Gainesville | Gainesville | Florida |
United States | University of Texas Medical Branch | Galveston | Texas |
United States | Adams Cancer Center | Gettysburg | Pennsylvania |
United States | Glendale Adventist Medical Center | Glendale | California |
United States | Green Bay Oncology at Saint Vincent Hospital | Green Bay | Wisconsin |
United States | Green Bay Oncology Limited at Saint Mary's Hospital | Green Bay | Wisconsin |
United States | Saint Vincent Hospital Cancer Center at Saint Mary's | Green Bay | Wisconsin |
United States | Saint Vincent Hospital Cancer Center Green Bay | Green Bay | Wisconsin |
United States | Greenville Health System Cancer Institute-Eastside | Greenville | South Carolina |
United States | Saint Francis Hospital | Greenville | South Carolina |
United States | Cherry Tree Cancer Center | Hanover | Pennsylvania |
United States | Smilow Cancer Hospital Care Center at Saint Francis | Hartford | Connecticut |
United States | Ingalls Memorial Hospital | Harvey | Illinois |
United States | Penn State Milton S Hershey Medical Center | Hershey | Pennsylvania |
United States | M D Anderson Cancer Center | Houston | Texas |
United States | Hutchinson Area Health Care | Hutchinson | Minnesota |
United States | Centerpoint Medical Center LLC | Independence | Missouri |
United States | IU Health Methodist Hospital | Indianapolis | Indiana |
United States | Green Bay Oncology - Iron Mountain | Iron Mountain | Michigan |
United States | Allegiance Health | Jackson | Michigan |
United States | Baptist MD Anderson Cancer Center | Jacksonville | Florida |
United States | Baptist Medical Center South | Jacksonville | Florida |
United States | Integrated Community Oncology Network-Southside Cancer Center | Jacksonville | Florida |
United States | University of Florida Health Science Center - Jacksonville | Jacksonville | Florida |
United States | Integrated Community Oncology Network-Florida Cancer Center Beaches | Jacksonville Beach | Florida |
United States | Jupiter Medical Center | Jupiter | Florida |
United States | Borgess Medical Center | Kalamazoo | Michigan |
United States | Bronson Methodist Hospital | Kalamazoo | Michigan |
United States | West Michigan Cancer Center | Kalamazoo | Michigan |
United States | Heartland Hematology and Oncology Associates Incorporated | Kansas City | Missouri |
United States | North Kansas City Hospital | Kansas City | Missouri |
United States | Research Medical Center | Kansas City | Missouri |
United States | Saint Joseph Health Center | Kansas City | Missouri |
United States | Saint Luke's Hospital of Kansas City | Kansas City | Missouri |
United States | Truman Medical Center | Kansas City | Missouri |
United States | Cheshire Medical Center-Dartmouth-Hitchcock Keene | Keene | New Hampshire |
United States | Kettering Medical Center | Kettering | Ohio |
United States | Wellmont Holston Valley Hospital and Medical Center | Kingsport | Tennessee |
United States | Thompson Cancer Survival Center | Knoxville | Tennessee |
United States | Thompson Cancer Survival Center - West | Knoxville | Tennessee |
United States | Gundersen Lutheran Medical Center | La Crosse | Wisconsin |
United States | Sparrow Hospital | Lansing | Michigan |
United States | Dartmouth Hitchcock Medical Center | Lebanon | New Hampshire |
United States | Saint Luke's East - Lee's Summit | Lee's Summit | Missouri |
United States | Beebe Medical Center | Lewes | Delaware |
United States | Liberty Radiation Oncology Center | Liberty | Missouri |
United States | Saint Mary Mercy Hospital | Livonia | Michigan |
United States | Logan Regional Hospital | Logan | Utah |
United States | The James Graham Brown Cancer Center at University of Louisville | Louisville | Kentucky |
United States | Covenant Medical Center-Lakeside | Lubbock | Texas |
United States | University of Wisconsin Hospital and Clinics | Madison | Wisconsin |
United States | Minnesota Oncology Hematology PA-Maplewood | Maplewood | Minnesota |
United States | Saint John's Hospital - Healtheast | Maplewood | Minnesota |
United States | Bay Area Medical Center | Marinette | Wisconsin |
United States | Mount Sinai Medical Center | Miami Beach | Florida |
United States | Upper Delaware Valley Cancer Center | Milford | Pennsylvania |
United States | Froedtert and the Medical College of Wisconsin | Milwaukee | Wisconsin |
United States | Abbott-Northwestern Hospital | Minneapolis | Minnesota |
United States | Hennepin County Medical Center | Minneapolis | Minnesota |
United States | Mobile Infirmary Medical Center | Mobile | Alabama |
United States | Virtua Memorial | Mount Holly | New Jersey |
United States | Cottonwood Hospital Medical Center | Murray | Utah |
United States | Intermountain Medical Center | Murray | Utah |
United States | Memorial Sloan Kettering Cancer Center | New York | New York |
United States | Christiana Care Health System-Christiana Hospital | Newark | Delaware |
United States | Southwest VA Regional Cancer Center | Norton | Virginia |
United States | Thompson Cancer Survival Center at Methodist | Oak Ridge | Tennessee |
United States | ProHealth Oconomowoc Memorial Hospital | Oconomowoc | Wisconsin |
United States | Green Bay Oncology - Oconto Falls | Oconto Falls | Wisconsin |
United States | McKay-Dee Hospital Center | Ogden | Utah |
United States | University of Oklahoma Health Sciences Center | Oklahoma City | Oklahoma |
United States | Nebraska Methodist Hospital | Omaha | Nebraska |
United States | UC Irvine Health/Chao Family Comprehensive Cancer Center | Orange | California |
United States | 21st Century Oncology-Orange Park | Orange Park | Florida |
United States | Menorah Medical Center | Overland Park | Kansas |
United States | Saint Luke's South Hospital | Overland Park | Kansas |
United States | 21st Century Oncology-Palatka | Palatka | Florida |
United States | Bay Medical Center | Panama City | Florida |
United States | Singing River Hospital | Pascagoula | Mississippi |
United States | Saint Joseph Mercy Oakland | Pontiac | Michigan |
United States | Lake Huron Medical Center | Port Huron | Michigan |
United States | Kansas City NCI Community Oncology Research Program | Prairie Village | Kansas |
United States | Utah Valley Regional Medical Center | Provo | Utah |
United States | Rapid City Regional Hospital | Rapid City | South Dakota |
United States | Renown Regional Medical Center | Reno | Nevada |
United States | Reid Health | Richmond | Indiana |
United States | Virginia Commonwealth University/Massey Cancer Center | Richmond | Virginia |
United States | North Memorial Medical Health Center | Robbinsdale | Minnesota |
United States | Highland Hospital | Rochester | New York |
United States | University of Rochester | Rochester | New York |
United States | Sutter Cancer Centers Radiation Oncology Services-Roseville | Roseville | California |
United States | Rutherford Hospital | Rutherfordton | North Carolina |
United States | Mercy General Hospital Radiation Oncology Center | Sacramento | California |
United States | Sutter Medical Center Sacramento | Sacramento | California |
United States | University of California Davis Comprehensive Cancer Center | Sacramento | California |
United States | Saint Mary's of Michigan | Saginaw | Michigan |
United States | Integrated Community Oncology Network-Flager Cancer Center | Saint Augustine | Florida |
United States | Dixie Medical Center Regional Cancer Center | Saint George | Utah |
United States | Norris Cotton Cancer Center-North | Saint Johnsbury | Vermont |
United States | Heartland Regional Medical Center | Saint Joseph | Missouri |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Metro Minnesota Community Oncology Research Consortium | Saint Louis Park | Minnesota |
United States | Park Nicollet Clinic - Saint Louis Park | Saint Louis Park | Minnesota |
United States | Regions Hospital | Saint Paul | Minnesota |
United States | United Hospital | Saint Paul | Minnesota |
United States | Siteman Cancer Center at Saint Peters Hospital | Saint Peters | Missouri |
United States | Salem Hospital | Salem | Oregon |
United States | UH Seidman Cancer Center at Salem Regional Medical Center | Salem | Ohio |
United States | Huntsman Cancer Institute/University of Utah | Salt Lake City | Utah |
United States | Intermountain Health Care | Salt Lake City | Utah |
United States | LDS Hospital | Salt Lake City | Utah |
United States | Utah Cancer Specialists-Salt Lake City | Salt Lake City | Utah |
United States | Memorial Health University Medical Center | Savannah | Georgia |
United States | Arizona Oncology Services Foundation | Scottsdale | Arizona |
United States | Saint Francis Regional Medical Center | Shakopee | Minnesota |
United States | Shawnee Mission Medical Center-KCCC | Shawnee Mission | Kansas |
United States | Sparta Cancer Treatment Center | Sparta | New Jersey |
United States | Spartanburg Medical Center | Spartanburg | South Carolina |
United States | Cancer Research for the Ozarks NCORP | Springfield | Missouri |
United States | CoxHealth South Hospital | Springfield | Missouri |
United States | Mercy Hospital Springfield | Springfield | Missouri |
United States | Saint John's Hospital | Springfield | Illinois |
United States | Green Bay Oncology - Sturgeon Bay | Sturgeon Bay | Wisconsin |
United States | Upper Valley Medical Center | Troy | Ohio |
United States | The University of Arizona Medical Center-University Campus | Tucson | Arizona |
United States | Sutter Cancer Centers Radiation Oncology Services-Vacaville | Vacaville | California |
United States | Virtua Voorhees | Voorhees | New Jersey |
United States | Ridgeview Medical Center | Waconia | Minnesota |
United States | Saint John Macomb-Oakland Hospital | Warren | Michigan |
United States | ProHealth Waukesha Memorial Hospital | Waukesha | Wisconsin |
United States | University Pointe | West Chester | Ohio |
United States | Reading Hospital | West Reading | Pennsylvania |
United States | Wheeling Hospital/Schiffler Cancer Center | Wheeling | West Virginia |
United States | Minnesota Oncology Hematology PA-Woodbury | Woodbury | Minnesota |
United States | Cancer Treatment Center | Wooster | Ohio |
United States | Greene Memorial Hospital | Xenia | Ohio |
United States | North Star Lodge Cancer Center at Yakima Valley Memorial Hospital | Yakima | Washington |
United States | WellSpan Health-York Hospital | York | Pennsylvania |
Lead Sponsor | Collaborator |
---|---|
National Cancer Institute (NCI) | NRG Oncology, Radiation Therapy Oncology Group |
United States, Canada, Saudi Arabia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of Patients Achieving 6-month Progression-free Survival (6mPFS) | This study utilized a two-stage phase II design (Stage 1B and 2). The primary endpoint of 6-month progression-free survival (6mPFS) would be assessed based on the patients combined from 1B and 2 if the study continued to Stage 2. Null hypothesis = 11%; alternative hypothesis = 25%. Simon's minmax 2-stage design was used with type I and type II error both set at 10%. If the first stage met its criteria (see secondary outcome measure), then accrual would continue, otherwise there would be no further accrual and the alternative hypothesis would be rejected. Following Stage 2 accrual completion and 6 months of follow-up, if 9 or more patients were alive without progression by 6 months, the null hypothesis would be rejected in favor of the alternative. | Registration to 6 months | |
Secondary | Number of Patients Achieving Objective Response (Partial or Complete Response) OR 6-month Progression-free Survival (6mPFS) | Study design and efficacy determination uses the hybrid endpoint of 6mPFS or complete/partial response of any duration prior to or at 6 months. Null hypothesis = 11%; alternative hypothesis = 25%. Simon's minmax 2-stage design was used with type I and type II error both set at 10%. Stage 1 and 1B: If 2 or fewer patients were alive and progression-free at 6 months or achieved complete/partial response, then there would be no further accrual and the alternative hypothesis would be rejected. Otherwise accrual would continue to a total of 50 analyzable patients to address the primary endpoint. Complete Response: Complete disappearance of all enhancing tumor on consecutive CT or MRI scans at least 1 month apart; off corticosteroids; neurologically stable/improved. Partial Response: = 50% decrease in size of enhancing tumor on consecutive CT or MRI scans at least 1 month apart; corticosteroids stable/reduced; neurologically stable/improved. | Registration to 6 months | |
Secondary | Overall Survival | Survival time is defined as time from randomization to date of death from any cause and is estimated by the Kaplan-Meier method. Patients last known to be alive are censored at the date of last contact. The study is not designed for a comparison of the treatment arms to each other. | Analysis occurs after all patients have been on study for at least 6 months. (Patients are followed from registration to death or study termination whichever occurs first.) | |
Secondary | Treatment Response Rates at Six Months | Best response is assessed using standard criteria for patients with malignant gliomas (Macdonald 1990) as reported by the site. Complete response (CR): Complete disappearance of all enhancing tumor on consecutive CT or MRI scans at least 1 month apart; off corticosteroids; neurologically stable/improved. Partial response (PR): = 50% decrease in size of enhancing tumor on consecutive CT or MRI scans at least 1 month apart; corticosteroids stable/reduced; neurologically stable/improved. Stable disease (SD): Does not qualify for CR, PR, or PD. Progressive disease (PD): = 25% increase in the size of enhancing tumor or any new tumor; neurologically worse; steroids stable/increased. The best tumor response is defined as the best radiographic response for patients evaluable for radiographic response prior to progression, up to six months. The study is not designed for a comparison of the treatment arms to each other. | From registration to 6 months | |
Secondary | Progression-free Survival | Progression-free survival time is measured from randomization to the date of first progression or death, else the last follow-up date on which the patient was reported alive, and is estimated by the Kaplan-Meier method. Progression is defined as = 25% increase in the size of enhancing tumor or any new tumor, neurologically worse, or steroids stable/increased. The study is not designed for a comparison of the treatment arms to each other. | Analysis occurs after all patients have been on study for at least 6 months. (Patients are followed from registration to death or study termination whichever occurs first.) | |
Secondary | Rate of Adverse Events | The rate of patients' worst overall grade of adverse event is reported. Adverse events are graded using CTCAE v3.0. Grade refers to the severity of the AE. The CTCAE v3.0 assigns Grades 1 through 5 with unique clinical descriptions of severity for each AE based on this general guideline: Grade 1 Mild AE, Grade 2 Moderate AE, Grade 3 Severe AE, Grade 4 Life-threatening or disabling AE, Grade 5 Death related to AE. The study is not designed for a comparison of the treatment arms to each other. | Analysis occurs after all patients have been on study for at least 6 months. (Patients are followed from registration to death or study termination whichever occurs first.) | |
Secondary | Correlation of Molecular Markers and Tumor Response | The following markers were examined: p-SRC, PDGFR, EPHA2, c-KIT. Patients were categorized based on the number of positive molecular markers they had: 2 vs. 3 and 4. Correlation of marker category and best tumor response was tested using Fisher's exact test. The best tumor response is defined as the best radiographic response for patients evaluable for radiographic response prior to progression up to six months. Patients are combined from the two treatment arms. | From registration to 6 months | |
Secondary | Correlation of Pharmacokinetic Data With Dosing, Toxicity, and Efficacy | Sufficient pharmacokinetic data was not obtained. | Analysis occurs after all patients have been on study for at least 6 months. (Patients are followed from registration to death or study termination whichever occurs first.) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT02530502 -
Radiation Therapy With Temozolomide and Pembrolizumab in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 1 | |
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT00238303 -
Vorinostat in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT02227901 -
Tipifarnib, Radiation Therapy, and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 1 | |
Completed |
NCT00049387 -
Tipifarnib, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma
|
Phase 1 | |
Completed |
NCT02015819 -
Genetically Modified Neural Stem Cells, Flucytosine, and Leucovorin for Treating Patients With Recurrent High-Grade Gliomas
|
Phase 1 | |
Active, not recruiting |
NCT02179086 -
Dose-Escalated Photon IMRT or Proton Beam Radiation Therapy Versus Standard-Dose Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
|
Phase 2 | |
Recruiting |
NCT04573140 -
A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM)
|
Phase 1 | |
Active, not recruiting |
NCT00823797 -
Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma
|
Phase 2 | |
Completed |
NCT00045565 -
Arsenic Trioxide Plus Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Completed |
NCT01977677 -
Plerixafor After Radiation Therapy and Temozolomide in Treating Patients With Newly Diagnosed High Grade Glioma
|
Phase 1/Phase 2 | |
Completed |
NCT01648348 -
Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme
|
Phase 1/Phase 2 | |
Completed |
NCT00004262 -
Radiation Therapy and Gadolinium Texaphyrin in Treating Patients With Supratentorial Glioblastoma Multiforme
|
Phase 1 | |
Terminated |
NCT01996527 -
3T MRI Biomarkers of Glioma Treatment Response
|
Early Phase 1 | |
Terminated |
NCT01575275 -
Aminolevulinic Acid in Visualizing a Tumor During Surgery in Patients With Glioblastoma Multiforme
|
Phase 2 | |
Completed |
NCT01119599 -
RO4929097, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Malignant Glioma
|
Phase 1 | |
Completed |
NCT01131234 -
Gamma-Secretase Inhibitor RO4929097 and Cediranib Maleate in Treating Patients With Advanced Solid Tumors
|
Phase 1 | |
Terminated |
NCT01103375 -
Erlotinib Hydrochloride and Isotretinoin in Treating Patients With Recurrent Malignant Glioma
|
Phase 1 | |
Completed |
NCT00459381 -
Pazopanib in Treating Patients With Recurrent Glioblastoma
|
Phase 2 | |
Completed |
NCT00316849 -
Temsirolimus, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme
|
Phase 1 |